Equity Overview
Price & Market Data
Price: $31.58
Daily Change: +$0.25 / 0.79%
Daily Range: $30.01 - $31.61
Market Cap: $1,685,490,816
Daily Volume: 543,473
Performance Metrics
1 Week: 8.19%
1 Month: 7.31%
3 Months: 96.88%
6 Months: 208.4%
1 Year: 147.1%
YTD: 20.12%
Company Details
Employees: 60
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.